GSK240705C44000
- 0.05
- 0.000.00%
GlaxoSmithKline Newsroom
GSK's RSV Vaccine Sales Outlook Dims After CDC's Narrowed Recommendation -- Market Talk
0619 GMT - GSK's sales outlook for its respiratory syncytial virus vaccine, Arexvy, could take a blow after U.S. health officials narrowed their age recommendation for RSV shots last week, Citi analys
Citi Sticks to Their Buy Rating for GlaxoSmithKline (GSK)
Brazil and Thailand Become First Malaria-endemic Countries to Launch New Single-dose Radical Cure Medicine to Prevent the Relapse of Plasmodium Vivax Malaria
Launch of single-dose tafenoquine, co-administered with chloroquine, is another step closer to global elimination of malaria The development and launch of this new treatment is the result of a partner
Should We Be Delighted With GSK Plc's (LON:GSK) ROE Of 36%?
UBS Sticks to Its Buy Rating for GlaxoSmithKline (GSK)
GSk Snaps Six Straight Days of Losses
GSK Will Pay Up to $1.5 Billion for CureVac's MRNA Vaccines -- Barrons.com
By Josh Nathan-Kazis The drugmaker GSK plunged into the messenger RNA-based vaccine market Wednesday, announcing it will buy the rights to experimental influenza and Covid-19 mRNA vaccines from the b
Sector Update: Health Care Stocks Steady Pre-Bell Wednesday
Health care stocks were steady pre-bell Wednesday as the Health Care Select Sector SPDR Fund (XLV) and iShares Biotechnology ETF (IBB) were inactive recently. CureVac (CVAC) and GSK (GSK) said they re
Looming Holiday Break Stifles US Equity Futures Pre-Bell
US equity futures were flat before Wednesday's opening bell as traders refrained from making big bets ahead of the Independence Day holiday. Dow Jones Industrial Average futures, the S&P 500 futures a
Sector Update: Health Care
Health care stocks were advancing pre-bell Wednesday, with the Health Care Select Sector SPDR Fund (XLV) up 0.1% and the iShares Biotechnology ETF (IBB) was nearly 18% higher recently. CureVac (CVAC)
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday Ahead of Economic Data Deluge
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was flat and the actively traded Invesco QQQ Trust (QQQ) was 0.03% lower in Wednesday's premarket activity as markets traded mixed ah
GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
Wednesday, GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) announced they have restructured their existing collaboration into a new licensing agreement, allowing the companies to prioritize investme
GSK to Buy CureVac's Covid-19, Flu Vaccine Rights for Up to $1.56 Bln
GSK struck a deal to buy the rights to CureVac's Covid-19 and flu vaccines for up to 1.45 billion euros ($1.56 billion), in a bid to regain ground lost to newcomers to the vaccine market during the pandemic.
Update: Market Chatter: Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits
(Updates with statement from GSK in fourth and fifth paragraphs.) A Delaware Superior Court judge rejected an appeal from GSK (GSK) and other drugmakers to overturn a ruling that cleared the way for o
Trending Tickers: SoftBank, Reddit, Vodafone, GSK
CureVac Shares Surge Premarket After Expanded Licensing Deal With GSK -- Market Talk
0938 GMT - CureVac's shares soared in premarket trading after the company ceded full rights to its influenza and Covid-19 mRNA vaccine candidates to GSK, part of a strategic restructuring and cost-cut
Biggest Stock Movers Today: PARAA, CVAC, and More
CureVac Enters Into New Licensing Agreement With GSK; to Implement 'Significant' Restructuring; Shares Rise Pre-Bell
CureVac (CVAC) and GSK (GSK) said Wednesday that they have restructured their existing partnership into a new licensing agreement that will allow each company to prioritize investment and focus on the
GlaxoSmithKline (GSK.US) acquires control of multiple vaccine development programs from German partners involving up to €1.45 billion.
United Kingdom pharmaceutical giant glaxosmithkline (GSK.US) announced on Wednesday that it will rebuild its partnership with German biotech company curevac and take control of the joint development of multiple vaccines. GSK will pay CureVac an upfront payment of 400 million euros and up to an additional 1.05 billion euros for development/regulatory approval and sales milestones. The two companies have been working together since 2020 to develop a variety of infectious disease vaccines using messenger ribonucleic acid technology (mRNA). CureVac sold multiple vaccine development projects through this trade and obtained the upfront payment to provide
US stock market abnormal <strong>Curevac</strong> rose nearly 20% before the market, expanded the mRNA vaccine cooperation agreement with <strong>GlaxoSmithKline</strong>, and planed to cut 30% of staff.
On July 3, Gelunhui, CureVac (CVAC.US), a German vaccine company, rose nearly 20% before pre-market trading, reporting $4. On the news front, GlaxoSmithKline and CureVac have redrafted their mRNA vaccine collaboration agreement in a new licensing agreement, giving GlaxoSmithKline the full rights to develop flu and COVID-19 candidate vaccines (including combination vaccines). CureVac will receive a prepayment of 400 million euros, as well as up to 1.05 billion euros in milestones and royalties. In addition, CureVac has begun a global strategy reorganization plan, which includes a 30% reduction in staff.